BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

742 related articles for article (PubMed ID: 15249058)

  • 1. Characteristics, epidemiology and clinical importance of emerging strains of Gram-negative bacilli producing extended-spectrum beta-lactamases.
    Shah AA; Hasan F; Ahmed S; Hameed A
    Res Microbiol; 2004; 155(6):409-21. PubMed ID: 15249058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat.
    Bradford PA
    Clin Microbiol Rev; 2001 Oct; 14(4):933-51, table of contents. PubMed ID: 11585791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study].
    Gür D; Gülay Z; Akan OA; Aktaş Z; Kayacan CB; Cakici O; Eraç B; Gültekin M; Oğünç D; Söyletir G; Unal N; Uysal S
    Mikrobiyol Bul; 2008 Oct; 42(4):537-44. PubMed ID: 19149074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinically important beta-lactamases of gram-negative bacteria: extended-spectrum beta-lactamases (ESBL)].
    Hrabák J
    Epidemiol Mikrobiol Imunol; 2007 Aug; 56(3):103-11. PubMed ID: 17900058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidrug resistance in Gram-negative bacteria that produce extended-spectrum beta-lactamases (ESBLs).
    Giamarellou H
    Clin Microbiol Infect; 2005 Jul; 11 Suppl 4():1-16. PubMed ID: 15953019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of extended-spectrum beta-lactamases in South America.
    Villegas MV; Kattan JN; Quinteros MG; Casellas JM
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():154-8. PubMed ID: 18154539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of extended spectrum beta-lactamase among multidrug resistant gram-negative isolates from a general hospital in Saudi Arabia.
    Kader AA; Kumar AK
    Saudi Med J; 2004 May; 25(5):570-4. PubMed ID: 15138522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotypic confirmation of extended-spectrum B-lactamases (ESBL) in clinical isolates of Escherichia coli and Klebsiella pneumoniae at the San Juan Veterans Affairs Medical Center.
    Del Carmen Rodríguez M; Vera DE; Ramírez-Ronda CH; Saavedra S
    P R Health Sci J; 2004 Sep; 23(3):207-15. PubMed ID: 15631176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended spectrum beta-lactamases among Gram-negative bacteria of nosocomial origin from an intensive care unit of a tertiary health facility in Tanzania.
    Ndugulile F; Jureen R; Harthug S; Urassa W; Langeland N
    BMC Infect Dis; 2005 Oct; 5():86. PubMed ID: 16225701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minor extended-spectrum beta-lactamases.
    Naas T; Poirel L; Nordmann P
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():42-52. PubMed ID: 18154527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system.
    Lewis JS; Herrera M; Wickes B; Patterson JE; Jorgensen JH
    Antimicrob Agents Chemother; 2007 Nov; 51(11):4015-21. PubMed ID: 17724160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Broad-spectrum beta-lactamases in Gram-negative bacteria].
    Sundsfjord A; Simonsen GS; Haldorsen B; Lundblad EW; Samuelsen O
    Tidsskr Nor Laegeforen; 2008 Dec; 128(23):2741-5. PubMed ID: 19079424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases.
    Calbo E; Romaní V; Xercavins M; Gómez L; Vidal CG; Quintana S; Vila J; Garau J
    J Antimicrob Chemother; 2006 Apr; 57(4):780-3. PubMed ID: 16492721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing extended-spectrum beta-lactamase production and quinolone resistance among Gram-negative bacilli causing intra-abdominal infections in the Asia/Pacific region: data from the Smart Study 2002-2006.
    Ko WC; Hsueh PR
    J Infect; 2009 Aug; 59(2):95-103. PubMed ID: 19564044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms.
    Jones RN; Sader HS; Fritsche TR
    Diagn Microbiol Infect Dis; 2005 May; 52(1):71-4. PubMed ID: 15878447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology of infections caused by multiresistant gram-negatives: ESBLs, MBLs, panresistant strains.
    Rossolini GM; Mantengoli E; Docquier JD; Musmanno RA; Coratza G
    New Microbiol; 2007 Jul; 30(3):332-9. PubMed ID: 17802921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concentration-dependency of beta-lactam-induced filament formation in Gram-negative bacteria.
    Buijs J; Dofferhoff AS; Mouton JW; Wagenvoort JH; van der Meer JW
    Clin Microbiol Infect; 2008 Apr; 14(4):344-9. PubMed ID: 18261128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining an extended-spectrum beta-lactamase.
    Livermore DM
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():3-10. PubMed ID: 18154524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and antimicrobial susceptibility of extended-spectrum beta-lactamase-producing bacteria in intensive care units of Sanandaj general hospitals (Kurdistan, Iran).
    Ramazanzadeh R; Chitsaz M; Bahmani N
    Chemotherapy; 2009; 55(4):287-92. PubMed ID: 19521074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The current state of multidrug-resistant gram-negative bacilli in North America.
    Nicasio AM; Kuti JL; Nicolau DP
    Pharmacotherapy; 2008 Feb; 28(2):235-49. PubMed ID: 18225969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.